Table 5

Changes in body composition by DEXA

	Placebo (n=16)	Teduglutide 0.10 mg/kg/day (n=32)	p1 Value	Teduglutide 0.05 mg/kg/day (n=35)	p2 Value
FM, kg
Baseline	n=16	n=31	0.80	n=34	0.12
Baseline	15.95±5.50	15.46±6.55		13.22±5.78
Week 24	n=14	n=29	0.66	n=28	0.07
Week 24	16.50±4.94	15.64±6.70		13.10±5.93
Absolute change	n=14	n=29	0.19	n=27	0.86
Absolute change	−0.63±1.88	0.38±1.98		−0.34±2.38
Relative change (%)	n=14	n=29	0.21	n=27	1.00
Relative change (%)	−3.8±11.0	4.6±16.5		−1.6±22.2
LBM, kg
Baseline	n=16	n=31	0.60	n=34	0.89
Baseline	42.42±7.82	41.19±7.50		42.77±8.28
Week 24	n=14	n=29	0.55	n=28	0.37
Week 24	41.52±8.64	43.12±7.87		43.97±8.19
Absolute change	n=14	n=29	0.004	n=27	0.06
Absolute change	−0.52±1.18	1.53±2.37		0.82±2.17
Relative change (%)	n=14	n=29	0.0033	n=27	0.051
Relative change (%)	−1.4±3.0	3.8±5.9		2.0±5.2
TBBMC, kg
Baseline	n=16	n=31	0.003	n=34	0.03
Baseline	2.42±0.47	2.00±0.41		2.10±0.47
Week 24	n=15	n=29	0.017	n=28	0.079
Week 24	2.39±0.50	2.04±0.42		2.14±0.40
Absolute change	n=15	n=29	0.046	n=27	0.06
Absolute change	−0.016±0.05	0.010±0.045		0.009±0.048
Relative change (%)	n=15	n=29	0.045	n=27	0.09
Relative change (%)	−0.8±2.1	0.6±2.4		0.4±2.4

Values shown are mean±SD.
p1 and p2 values for treatment differences from a general linear model (GLM) method with dependent variable changes from baseline in the corresponding variables, independent variable treatment and corresponding variables at baseline as covariates.
FM, fat mass; LBM, lean body mass; TBBMC, total body bone mineral content.